Ghent University Academic Bibliography

Advanced

Generation and in vivo characterization of a chimeric αvβ5-targeting antibody 14C5 and its derivatives

Caroline Dumolyn, Steve Schoonooghe UGent, Lieselotte Moerman, Sara Neyt UGent, Jurgen Haustraete UGent and Filip De Vos UGent (2013) EJNMMI RESEARCH. 3.
abstract
Background: Previous studies showed that radiolabeled murine monoclonal antibody (mAb) 14C5 and its Fab and F(ab')2 fragments, targeting αvβ5 integrin, have promising properties for diagnostic and therapeutic applications in cancer. To diminish the risk of generating a human anti-mouse antibody response in patients, chimeric variants were created. The purpose of this study was to recombinantly produce chimeric antibody (chAb) derivatives of the murine mAb 14C5 and to evaluate the in vitro and in vivo characteristics. Methods: In vitro stability, specificity, and affinity of radioiodinated chAb and fragments (Iodo-Gen method) were examined on high-expressing αvβ5 A549 lung tumor cells. In vivo biodistribution and pharmacokinetic characteristics were studied in A549 lung tumor-bearing Swiss Nu/Nu mice. Results: Saturation binding experiments revealed high in vitro affinity of radioiodinated chAb, F(ab')2, and Fab, with dissociation constants (KD) of 1.19 ± 0.19, 0.68 ± 0.10, and 2.11 ± 0.58 nM, respectively. ChAb 14C5 showed highest tumor uptake (approximately 10%ID/g) at 24 h post injection, corresponding with other high-affinity Abs. ChF(ab')2 and chFab fragments showed faster clearance from the blood compared to the intact Ab. Conclusions: The chimerization of mAb 14C5 and its fragments has no or negligible effect on the properties of the antibody. In vitro and in vivo properties show that the chAb 14C5 is promising for radioimmunotherapy, due to its high maximum tumor uptake and its long retention in the tumor. The chF(ab')2 fragment shows a similar receptor affinity and a faster blood clearance, causing less non-specific retention than the chAb. Due to their fast blood clearance, the fragments show high potential for radioimmunodiagnosis.
Please use this url to cite or link to this publication:
author
organization
alternative title
Generation and in vivo characterization of a chimeric alpha v beta 5-targeting antibody 14C5 and its derivatives
year
type
journalArticle (original)
publication status
published
subject
keyword
Oncology, 14C5 antibody, Integrin αvβ5, RIT, RID
journal title
EJNMMI RESEARCH
EJNMMI Res.
volume
3
article number
25
pages
10 pages
ISSN
2191-219X
DOI
10.1186/2191-219X-3-25
language
English
UGent publication?
yes
classification
A2
copyright statement
I have retained and own the full copyright for this publication
id
3233604
handle
http://hdl.handle.net/1854/LU-3233604
date created
2013-06-03 14:43:35
date last changed
2017-02-16 11:34:48
@article{3233604,
  abstract     = {Background: Previous studies showed that radiolabeled murine monoclonal antibody (mAb) 14C5 and its Fab and F(ab')2 fragments, targeting \ensuremath{\alpha}v\ensuremath{\beta}5 integrin, have promising properties for diagnostic and therapeutic applications in cancer. To diminish the risk of generating a human anti-mouse antibody response in patients, chimeric variants were created. The purpose of this study was to recombinantly produce chimeric antibody (chAb) derivatives of the murine mAb 14C5 and to evaluate the in vitro and in vivo characteristics.
Methods: In vitro stability, specificity, and affinity of radioiodinated chAb and fragments (Iodo-Gen method) were examined on high-expressing \ensuremath{\alpha}v\ensuremath{\beta}5 A549 lung tumor cells. In vivo biodistribution and pharmacokinetic characteristics were studied in A549 lung tumor-bearing Swiss Nu/Nu mice.
Results: Saturation binding experiments revealed high in vitro affinity of radioiodinated chAb, F(ab')2, and Fab, with dissociation constants (KD) of 1.19 {\textpm} 0.19, 0.68 {\textpm} 0.10, and 2.11 {\textpm} 0.58 nM, respectively. ChAb 14C5 showed highest tumor uptake (approximately 10\%ID/g) at 24 h post injection, corresponding with other high-affinity Abs. ChF(ab')2 and chFab fragments showed faster clearance from the blood compared to the intact Ab.
Conclusions: The chimerization of mAb 14C5 and its fragments has no or negligible effect on the properties of the antibody. In vitro and in vivo properties show that the chAb 14C5 is promising for radioimmunotherapy, due to its high maximum tumor uptake and its long retention in the tumor. The chF(ab')2 fragment shows a similar receptor affinity and a faster blood clearance, causing less non-specific retention than the chAb. Due to their fast blood clearance, the fragments show high potential for radioimmunodiagnosis.},
  articleno    = {25},
  author       = {Dumolyn, Caroline and Schoonooghe, Steve and Moerman, Lieselotte and Neyt, Sara and Haustraete, Jurgen and De Vos, Filip},
  issn         = {2191-219X},
  journal      = {EJNMMI RESEARCH},
  keyword      = {Oncology,14C5 antibody,Integrin \ensuremath{\alpha}v\ensuremath{\beta}5,RIT,RID},
  language     = {eng},
  pages        = {10},
  title        = {Generation and in vivo characterization of a chimeric \ensuremath{\alpha}v\ensuremath{\beta}5-targeting antibody 14C5 and its derivatives},
  url          = {http://dx.doi.org/10.1186/2191-219X-3-25},
  volume       = {3},
  year         = {2013},
}

Chicago
Dumolyn, Caroline, Steve Schoonooghe, LIESELOTTE MOERMAN, Sara Neyt, Jurgen Haustraete, and Filip De Vos. 2013. “Generation and in Vivo Characterization of a Chimeric Αvβ5-targeting Antibody 14C5 and Its Derivatives.” Ejnmmi Research 3.
APA
Dumolyn, C., Schoonooghe, S., MOERMAN, L., Neyt, S., Haustraete, J., & De Vos, F. (2013). Generation and in vivo characterization of a chimeric αvβ5-targeting antibody 14C5 and its derivatives. EJNMMI RESEARCH, 3.
Vancouver
1.
Dumolyn C, Schoonooghe S, MOERMAN L, Neyt S, Haustraete J, De Vos F. Generation and in vivo characterization of a chimeric αvβ5-targeting antibody 14C5 and its derivatives. EJNMMI RESEARCH. 2013;3.
MLA
Dumolyn, Caroline, Steve Schoonooghe, LIESELOTTE MOERMAN, et al. “Generation and in Vivo Characterization of a Chimeric Αvβ5-targeting Antibody 14C5 and Its Derivatives.” EJNMMI RESEARCH 3 (2013): n. pag. Print.